Flagship’s gene editing startup Tessera cuts jobs as it shifts resources to clinic
Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a spokesperson confirmed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
